Anixa Biosciences Inc
Financial highlights
| Metric | FY 10/31/25 | FY 10/31/24 | FY 10/31/23 | FY 10/31/22 | FY 10/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $210,000 | $210,000 | — | $512,000 |
| Research and development | $5.1M | $6.4M | $4.8M | $6.7M | $6.2M |
| Operating income | -$11.7M | -$13.8M | -$11.0M | -$13.9M | -$13.1M |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | -$13.0M |
| Balance Sheet | |||||
| Cash and equivalents | $1.2M | $1.3M | $915,000 | $12.4M | $29.1M |
| Current assets | $15.9M | $21.4M | $25.4M | $30.2M | $36.0M |
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M |
| Current liabilities | $2.0M | $2.5M | $2.0M | $2.0M | $1.3M |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M |
| Stockholders' equity | $15.2M | $20.0M | $24.3M | $29.0M | $35.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.2M | -$7.3M | -$6.2M | -$6.5M | -$4.9M |
| Stock-based compensation | $3.7M | $4.4M | $4.4M | $6.0M | $7.5M |
| Share repurchases | — | $6,000 | — | — | — |
Shares outstanding 33.5M · Free float 35.5%
Annual filing data through FY ended October 31, 2025; float as of July 8, 2026.